论文部分内容阅读
选择自体造血干细胞移植还是异基因造血干细胞移植治疗弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者需权衡治疗相关死亡率(treatment-related mortality,TRM)差异、自体移植物被肿瘤污染的可能、干细胞动员失败和异体移植物抗淋巴瘤效应等因素之间的利弊。国
The choice of autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma (DLBCL) requires treatment-related mortality (treatment-related mortality, TRM) difference, autologous graft was tumor The potential for contamination, the failure of stem cell mobilization and the effects of allograft anti-lymphoma effects. country